Published in J Cereb Blood Flow Metab on August 14, 2013
Non-additive modulation of synaptic transmission by serotonin, adenosine, and cholinergic modulators in the sensory thalamus. Front Cell Neurosci (2015) 0.75
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors. Curr Top Med Chem (2016) 0.75
[(18) F]Nifene test-retest reproducibility in first-in-human imaging of α4β2* nicotinic acetylcholine receptors. Synapse (2017) 0.75
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol (2004) 3.17
Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol (2001) 3.07
Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab (1996) 2.66
Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry (2006) 2.53
COMKAT: compartment model kinetic analysis tool. J Nucl Med (2001) 1.88
Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis. J Cereb Blood Flow Metab (1989) 1.71
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 1.44
Dynamic PET denoising with HYPR processing. J Nucl Med (2010) 1.35
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol (1995) 1.28
Models for computer simulation studies of input functions for tracer kinetic modeling with positron emission tomography. Int J Biomed Comput (1993) 1.27
Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol (2006) 1.22
In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med (2005) 1.18
Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab (2004) 1.16
Evaluation of objective functions for estimation of kinetic parameters. Med Phys (2006) 1.11
Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med (2010) 1.10
Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans Biomed Eng (1990) 1.08
High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb Blood Flow Metab (2009) 1.07
Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry (2012) 1.07
Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Pharmacol Exp Ther (2003) 1.02
Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology (2004) 1.02
Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse (2011) 0.98
In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab (2002) 0.91
Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach. J Cereb Blood Flow Metab (2007) 0.91
PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med (2012) 0.90
Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res (2000) 0.90
Robust experiment design for estimating myocardial beta adrenergic receptor concentration using PET. Med Phys (2007) 0.89
Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur Neuropsychopharmacol (2007) 0.88
The effects of lobeline on α4β2* nicotinic acetylcholine receptor binding and uptake of [(18)F]nifene in rats. J Neurosci Methods (2013) 0.84
Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat Disord (2003) 0.84
Estimation of local receptor density, B'max, and other parameters via multiple-injection positron emission tomography experiments. Methods Enzymol (2004) 0.84
Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography. Neuroscience (1998) 0.82
Concentration of dopamine transporters: to Bmax or not to Bmax? Synapse (1999) 0.81
5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate. Neuroimage (2013) 0.80
Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther (2005) 0.80
Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience (1999) 0.79
Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci (2009) 2.78
Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with 15O-water PET in elderly subjects at risk for Alzheimer's disease. NMR Biomed (2010) 1.85
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol (2009) 1.65
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proc Natl Acad Sci U S A (2013) 1.64
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging (2012) 1.41
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci (2011) 1.36
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One (2010) 1.34
Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and β3-adrenergic receptor activation. EJNMMI Res (2011) 1.31
Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials (2012) 1.27
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol (2007) 1.23
Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med (2006) 1.22
Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol (2006) 1.22
D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res (2006) 1.19
Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab (2004) 1.16
Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm (2012) 1.14
Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging (2013) 1.14
ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res (2012) 1.14
Evaluation of objective functions for estimation of kinetic parameters. Med Phys (2006) 1.11
Prenatal stress induces increased striatal dopamine transporter binding in adult nonhuman primates. Biol Psychiatry (2013) 1.10
Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition. Synapse (2007) 1.09
High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb Blood Flow Metab (2009) 1.07
In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials (2012) 1.07
Chelator-free synthesis of a dual-modality PET/MRI agent. Angew Chem Int Ed Engl (2013) 1.05
A [17F]-fluoromethane PET/TMS study of effective connectivity. Brain Res Bull (2004) 1.04
HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res (2011) 1.04
Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J Neurosci (2009) 1.04
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (2013) 1.03
In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles. ACS Nano (2015) 1.03
Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res (2005) 1.02
Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med (2012) 1.02
Moderate level fetal alcohol exposure and serotonin transporter gene promoter polymorphism affect neonatal temperament and limbic-hypothalamic-pituitary-adrenal axis regulation in monkeys. Biol Psychiatry (2007) 1.02
Moderate-level prenatal alcohol exposure alters striatal dopamine system function in rhesus monkeys. Alcohol Clin Exp Res (2005) 1.02
Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallypride. Synapse (2011) 1.02
Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm (2012) 1.01
Evaluation of F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Res (2011) 1.00
Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano (2015) 0.99
Production of 34m Cl and 38 Cl via the (d,α) reaction on 36 Ar and nat Ar gas at 8.4 MeV. Appl Radiat Isot (2010) 0.98
Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. Mol Pharm (2013) 0.97
PET Measurement of rCBF in the presence of a neurochemical tracer. J Neurosci Methods (2004) 0.97
Novel Preparation Methods of (52)Mn for ImmunoPET Imaging. Bioconjug Chem (2015) 0.97
A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve (2012) 0.96
18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies. J Nucl Med (2011) 0.96
The unrealized potential of (34m)Cl for radiopharmaceutical research with PET. Curr Radiopharm (2011) 0.96
Prenatal disturbance alters the size of the corpus callosum in young monkeys. Dev Psychobiol (2002) 0.95
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm (2014) 0.93
Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity. Synapse (2012) 0.93
An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primate. Nucl Med Biol (2011) 0.92
Improved kinetic analysis of dynamic PET data with optimized HYPR-LR. Med Phys (2012) 0.91
Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody. Mol Pharm (2012) 0.90
Nicotinic acetylcholine receptors in rat forebrain that bind ¹⁸F-nifene: relating PET imaging, autoradiography, and behavior. Synapse (2012) 0.90
PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med (2012) 0.90
Radiolabeled γ-AApeptides: a new class of tracers for positron emission tomography. Chem Commun (Camb) (2012) 0.90
(44)Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm (2014) 0.90
11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. Bioorg Med Chem (2004) 0.90
Evaluation of serotonin 5-HT(1A) receptors in rodent models using [¹⁸F]mefway PET. Synapse (2013) 0.89
Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105. Mol Pharm (2013) 0.89
11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J Nucl Med (2011) 0.88
Serotonin transporter genotype affects serotonin 5-HT1A binding in primates. J Neurosci (2013) 0.88
Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist, (R,S)-5-hydroxy-2-(N-propyl-N-(5'-(18)F-fluoropentyl)aminotetralin ((18)F-5-OH-FPPAT) in rodents and nonhuman primates. Nucl Med Biol (2004) 0.88
PET evidence for a role for striatal dopamine in the attentional blink: functional implications. J Cogn Neurosci (2012) 0.88
Measurement of 5-HT(1A) receptor density and in-vivo binding parameters of [(18)F]mefway in the nonhuman primate. J Cereb Blood Flow Metab (2012) 0.88
The homozygote VCP(R¹⁵⁵H/R¹⁵⁵H) mouse model exhibits accelerated human VCP-associated disease pathology. PLoS One (2012) 0.87
Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging. ACS Appl Mater Interfaces (2014) 0.87
Love to win or hate to Lose? Asymmetry of dopamine D2 receptor binding predicts sensitivity to reward versus punishment. J Cogn Neurosci (2013) 0.86
Evaluation of [18F]Mefway biodistribution and dosimetry based on whole-body PET imaging of mice. Mol Imaging Biol (2013) 0.86
Adrenergic pathway activation enhances brown adipose tissue metabolism: a [¹⁸F]FDG PET/CT study in mice. Nucl Med Biol (2013) 0.86